Physicians' Academy for Cardiovascular Education

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

3' education - Mar. 17, 2017

ACC 2017 Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patients, as a consequence of development of antibodies against the drug.

Educational information

The SPIRE 1 and SPIRE 2 trials were presented during Late-Breaking Clinical Trial Session 1 (March 17), ACC 2017, Washington DC, USA

Recorded at ACC 2017, Washington DC, USA.

Disclosures

Dr. Paul M. Ridker (Co-chair Executive Committee, SPIRE clinical trials program and director for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Boston, MA, USA)

Share this page with your colleagues and friends: